Claims Scope:

Patent issued May 28, 2021. 

Sequence Agnostic (and Gene Agnostic)  

Method of treating a patient with transduced CD4 T cells including transducing the CD4 T cells ex vivo with a viral delivery system encoding at least one genetic element (small RNA) capable of targeting a HIV RNA sequence.